These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1081 related articles for article (PubMed ID: 24895459)

  • 1. Cotargeting of epidermal growth factor receptor and PI3K overcomes PI3K-Akt oncogenic dependence in pancreatic ductal adenocarcinoma.
    Wong MH; Xue A; Julovi SM; Pavlakis N; Samra JS; Hugh TJ; Gill AJ; Peters L; Baxter RC; Smith RC
    Clin Cancer Res; 2014 Aug; 20(15):4047-58. PubMed ID: 24895459
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Upstream and Downstream Co-inhibition of Mitogen-Activated Protein Kinase and PI3K/Akt/mTOR Pathways in Pancreatic Ductal Adenocarcinoma.
    Wong MH; Xue A; Baxter RC; Pavlakis N; Smith RC
    Neoplasia; 2016 Jul; 18(7):425-35. PubMed ID: 27435925
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting ErbB3-mediated stromal-epithelial interactions in pancreatic ductal adenocarcinoma.
    Liles JS; Arnoletti JP; Kossenkov AV; Mikhaylina A; Frost AR; Kulesza P; Heslin MJ; Frolov A
    Br J Cancer; 2011 Aug; 105(4):523-33. PubMed ID: 21792199
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Amiloride sensitizes human pancreatic cancer cells to erlotinib in vitro through inhibition of the PI3K/AKT signaling pathway.
    Zheng YT; Yang HY; Li T; Zhao B; Shao TF; Xiang XQ; Cai WM
    Acta Pharmacol Sin; 2015 May; 36(5):614-26. PubMed ID: 25864651
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Disclosure of erlotinib as a multikinase inhibitor in pancreatic ductal adenocarcinoma.
    Conradt L; Godl K; Schaab C; Tebbe A; Eser S; Diersch S; Michalski CW; Kleeff J; Schnieke A; Schmid RM; Saur D; Schneider G
    Neoplasia; 2011 Nov; 13(11):1026-34. PubMed ID: 22131878
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PI3K/AKT/mTOR and sonic hedgehog pathways cooperate together to inhibit human pancreatic cancer stem cell characteristics and tumor growth.
    Sharma N; Nanta R; Sharma J; Gunewardena S; Singh KP; Shankar S; Srivastava RK
    Oncotarget; 2015 Oct; 6(31):32039-60. PubMed ID: 26451606
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MP470, a novel receptor tyrosine kinase inhibitor, in combination with Erlotinib inhibits the HER family/PI3K/Akt pathway and tumor growth in prostate cancer.
    Qi W; Cooke LS; Stejskal A; Riley C; Croce KD; Saldanha JW; Bearss D; Mahadevan D
    BMC Cancer; 2009 May; 9():142. PubMed ID: 19432987
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ginsenoside Rg3 enhances the anti-proliferative activity of erlotinib in pancreatic cancer cell lines by downregulation of EGFR/PI3K/Akt signaling pathway.
    Jiang J; Yuan Z; Sun Y; Bu Y; Li W; Fei Z
    Biomed Pharmacother; 2017 Dec; 96():619-625. PubMed ID: 29035827
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Atorvastatin delays progression of pancreatic lesions to carcinoma by regulating PI3/AKT signaling in p48Cre/+ LSL-KrasG12D/+ mice.
    Mohammed A; Qian L; Janakiram NB; Lightfoot S; Steele VE; Rao CV
    Int J Cancer; 2012 Oct; 131(8):1951-62. PubMed ID: 22287227
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ErbB3 expression promotes tumorigenesis in pancreatic adenocarcinoma.
    Liles JS; Arnoletti JP; Tzeng CW; Howard JH; Kossenkov AV; Kulesza P; Heslin MJ; Frolov A
    Cancer Biol Ther; 2010 Sep; 10(6):555-63. PubMed ID: 20647770
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PANC-1 pancreatic cancer cell growth inhibited by cucurmosin alone and in combination with an epidermal growth factor receptor-targeted drug.
    Wang C; Yang A; Zhang B; Yin Q; Huang H; Chen M; Xie J
    Pancreas; 2014 Mar; 43(2):291-7. PubMed ID: 24518510
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dacomitinib, an irreversible Pan-ErbB inhibitor significantly abrogates growth in head and neck cancer models that exhibit low response to cetuximab.
    Ather F; Hamidi H; Fejzo MS; Letrent S; Finn RS; Kabbinavar F; Head C; Wong SG
    PLoS One; 2013; 8(2):e56112. PubMed ID: 23405260
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Kaempferol potentiates the sensitivity of pancreatic cancer cells to erlotinib via inhibition of the PI3K/AKT signaling pathway and epidermal growth factor receptor.
    Zhang Z; Guo Y; Chen M; Chen F; Liu B; Shen C
    Inflammopharmacology; 2021 Oct; 29(5):1587-1601. PubMed ID: 34322786
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Monensin inhibits cell proliferation and tumor growth of chemo-resistant pancreatic cancer cells by targeting the EGFR signaling pathway.
    Wang X; Wu X; Zhang Z; Ma C; Wu T; Tang S; Zeng Z; Huang S; Gong C; Yuan C; Zhang L; Feng Y; Huang B; Liu W; Zhang B; Shen Y; Luo W; Wang X; Liu B; Lei Y; Ye Z; Zhao L; Cao D; Yang L; Chen X; Haydon RC; Luu HH; Peng B; Liu X; He TC
    Sci Rep; 2018 Dec; 8(1):17914. PubMed ID: 30559409
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Insights into erlotinib action in pancreatic cancer cells using a combined experimental and mathematical approach.
    Lange F; Rateitschak K; Kossow C; Wolkenhauer O; Jaster R
    World J Gastroenterol; 2012 Nov; 18(43):6226-34. PubMed ID: 23180942
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gemcitabine and CHK1 inhibition potentiate EGFR-directed radioimmunotherapy against pancreatic ductal adenocarcinoma.
    Al-Ejeh F; Pajic M; Shi W; Kalimutho M; Miranda M; Nagrial AM; Chou A; Biankin AV; Grimmond SM; ; Brown MP; Khanna KK
    Clin Cancer Res; 2014 Jun; 20(12):3187-97. PubMed ID: 24838526
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rapamycin synergizes with the epidermal growth factor receptor inhibitor erlotinib in non-small-cell lung, pancreatic, colon, and breast tumors.
    Buck E; Eyzaguirre A; Brown E; Petti F; McCormack S; Haley JD; Iwata KK; Gibson NW; Griffin G
    Mol Cancer Ther; 2006 Nov; 5(11):2676-84. PubMed ID: 17121914
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synergistic effect between erlotinib and MEK inhibitors in KRAS wild-type human pancreatic cancer cells.
    Diep CH; Munoz RM; Choudhary A; Von Hoff DD; Han H
    Clin Cancer Res; 2011 May; 17(9):2744-56. PubMed ID: 21385921
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metformin and erlotinib synergize to inhibit basal breast cancer.
    Lau YK; Du X; Rayannavar V; Hopkins B; Shaw J; Bessler E; Thomas T; Pires MM; Keniry M; Parsons RE; Cremers S; Szabolcs M; Maurer MA
    Oncotarget; 2014 Nov; 5(21):10503-17. PubMed ID: 25361177
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Opposite regulation by PI3K/Akt and MAPK/ERK pathways of tissue factor expression, cell-associated procoagulant activity and invasiveness in MDA-MB-231 cells.
    Hu C; Huang L; Gest C; Xi X; Janin A; Soria C; Li H; Lu H
    J Hematol Oncol; 2012 Jul; 5():16. PubMed ID: 22534171
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 55.